Get to know our clinical trials
Clinical trial of AMX 818 alone and with pembrolizumab in participants with HER2-expressing locally advanced or metastatic cancers
THE PURPOSE OF THIS CLINICAL TRIAL IS TO EVALUATE WHETHER THE AMX-818 TRIAL DRUG, ALONE OR IN COMBINATION WITH PEMBROLIZUMAB AT DIFFERENT DOSES, IS SAFE AND EFFECTIVE IN TREATING HUMAN CANCERS THAT PRODUCE A PROTEIN CALLED HER2 AND TO LEARN HOW YOUR BODY PROCESSES AND REACTS TO THE TRIAL DRUG.
Technical Summary
- PHASE I, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN, MULTI-CENTER STUDY OF THE SAFETY AND PHARMACOKINETICS OF AMX 818 ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS. IMMUNOTHERAPY
- Code EudraCT: .
- Protocol number: AMX-818-001
- Promoter: Amunix Pharmaceuticals, Inc.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.